Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Genomics & Proteomics
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Cancer Genomics & Proteomics

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Review Article

Application of Array-based Genomic and Epigenomic Technologies to Unraveling the Heterogeneous Nature of Breast Tumors: On the Road to Individualized Treatment

MARK ABRAMOVITZ and BRIAN LEYLAND-JONES
Cancer Genomics & Proteomics May 2007, 4 (3) 135-145;
MARK ABRAMOVITZ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BRIAN LEYLAND-JONES
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: leyland@emory.edu
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The recent application of genomic microarray technology to the molecular profiling of breast tumors has clearly demonstrated their heterogeneous nature. Targeted treatment strategies are having a clear impact on patient survival. It has also become apparent that accumulated mutations, genomic instability, epigenetic phenomena, genetic variability and environmental factors all contribute to the uniqueness of a patient's tumor. Novel genomic and epigenetic-based technologies have been or are being developed in order to greatly enhance the analysis of tumor samples including those samples previously thought unusable due to the fixation process, such as archival formalin-fixed paraffin-embedded (FFPE) samples. Patients and their tumors can now be studied with regard to genetic variation, genomic instability, gene expression, gene mutations, and methylation patterns. These areas of research are being made more accessible through genome-wide screening technologies and will, in the near future, rapidly expand our understanding of what contributes to the unique properties of each tumor and lead to the identification of genes that could be potential therapeutic targets for specific tumor subtypes. Application of these technologies to our understanding of breast cancer will undoubtedly have an impact on the individualization of treatment for breast cancer patients in the not to distant future.

Keywords:
  • Breast cancer
  • targeted therapies
  • DNA copy number alterations
  • microarrays
  • DASL assay
  • array-CGH
  • SNPs
  • epigenetics
  • methylation
  • review

Footnotes

    • Received April 12, 2007.
    • Accepted April 18, 2007.
  • Copyright© 2007 International Institute of Anticaner Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Cancer Genomics - Proteomics: 4 (3)
Cancer Genomics & Proteomics
Vol. 4, Issue 3
May-June 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cancer Genomics & Proteomics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Application of Array-based Genomic and Epigenomic Technologies to Unraveling the Heterogeneous Nature of Breast Tumors: On the Road to Individualized Treatment
(Your Name) has sent you a message from Cancer Genomics & Proteomics
(Your Name) thought you would like to see the Cancer Genomics & Proteomics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Application of Array-based Genomic and Epigenomic Technologies to Unraveling the Heterogeneous Nature of Breast Tumors: On the Road to Individualized Treatment
MARK ABRAMOVITZ, BRIAN LEYLAND-JONES
Cancer Genomics & Proteomics May 2007, 4 (3) 135-145;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Application of Array-based Genomic and Epigenomic Technologies to Unraveling the Heterogeneous Nature of Breast Tumors: On the Road to Individualized Treatment
MARK ABRAMOVITZ, BRIAN LEYLAND-JONES
Cancer Genomics & Proteomics May 2007, 4 (3) 135-145;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Molecular Profiling: Moving Away from Tumor Philately
  • Quantified Tumor T1 Is a Generic Early-Response Imaging Biomarker for Chemotherapy Reflecting Cell Viability
  • Google Scholar

Similar Articles

Cancer & Genome Proteomics

© 2023 Cancer Genomics & Proteomics

Powered by HighWire